AB S T R A C T The opsonophagocytic requirements of human sera containing endogenous complement for a variety of type Ia, and group B streptococcal strains were defined. Significant reduction (290%) in colonyforming units was noted after a 40-min incubation for the highly encapsulated, mouse-passed prototype strain 090 by sera containing moderate to high concentrations of antibody to type Ia polysaccharide (mean, 16.5 gg/ml), whereas bacterial growth occurred in 25 sera with low levels of specific antibody (mean, 2.1 ug/ml). This absolute requirement for a critical amount of specific antibody in promoting opsonophagocytic killing of strain 090 was not found when 18 fresh clinical type la isolates were tested. In antibody-deficient and agammaglobulinemic sera, respectively, mean reductions in colony-forming units of 94 and 95% were seen for fresh clinical isolates, whereas strain 090 was not killed by polymorphonuclear leukocytes in the presence of these sera. All strains required a considerable amount of specific antibody for alternative pathwaymediated opsonophagocytosis. That opsonophagocytic killing of clinical type Ia isolates was mediated by the classical pathway in a nonantibody-dependent fashion was shown when MgEGTA chelation of agammaglobulinernic serum or use of serum deficient in C2 resulted in bacterial growth. The addition of C2 to C2-deficient serum restored bactericidal activity of this serum. These experiments indicate that substances other than the exposed surface of the type Ta capsular polysac-
INTRODUCTION
Our previous studies (1-3) have indicated that neonates at significant risk for the development of invasive type III, group B streptococcal infection are those with a deficiency of maternally acquired antibody with specificity for the native type III capsular polysaccharide, although other host defense mechanisms may assist in limiting infection to mucous membranes. The mechanism by which this transplacentally acquired anticapsular antibody mediates protective immunity is incompletely understood. However, recently it has been demonstrated that human sera containing a critical amount of this antibody will initiate complementmediated opsonophagocytosis of type III organisms via both the classical and the alternative pathway. In the. absence of antibody, no opsonophagocytic killing occurs. Of interest, if the terminal sialic acid residue of the type III capsule is removed by neuraminidase treatment, nonantibody-dependent activation of the alternative pathway results, and type III organisms are ingested by polymorphonuclear leukocytes and killed (4) . How this antibody with specificity for the terminal sialic acid residues on the repeating unit of the type III capsular polysaccharide (5) permits activation of the alternative pathway is unknown. Utilization of this important mechanism of natural immunity by the host, however, is dependent upon the presence of sufficient concentrations of specific antibody.
Another serotype of group B Streptococcus respon-sbb-for invasive infection in neonates is type Ta. In contrast to type III strains, however, almost all of these infections have their onset in the first few days of life. The structures of the capsular polysaccharides of these two serotypes are similar in that terminal sialic acid residues completely mask underlying galactopyranose groups, although the specific linkages and locations of these two monosaccharides and other monosaccharide constituents are different (5, 6) . Some studies have suggested that a low level of antibody to type Ia polysaccharides in maternal serum, in a manner analogous to serotype III, is a risk factor for neonatal type Ta septicemia (7, 8 (10) . In addition, strains were passed 25 times daily into THB containing a 10% concentration of a single human serum that contained low levels of antibody to the type Ia polysaccharide (1.0 ug/ml). Aliquots of these laboratory-adapted strains were frozen at -70°C in THB until tested.
Mouse lethality tests. Select type Ia strains of group B Streptococcus were tested for virulence in mice in a way similar to previously described methods (10) . Strains were grown overnight in THB to a concentration of -5.0 X 108 CFU/ml. For calculation of LD5o, all dilutions of broth cultures were made in saline and injected intraperitoneally in 1-ml volumes. Dead mice were counted and removed from their cages at 24-h intervals. The LD50 for a given strain was estimated by the method of Reed and Muench (11) .
Electron microscopy. (18) was employed. The opsonic reaction mixture contained 0.1 ml of WBC suspension (_1 X 106 WBC), 0.1 ml of bacterial suspension (_5 X 106 CFU), and 0.1 ml of human serum that contained endogenous complement. When exogenous complement was employed with heated serum as an antibody source or when human C2 was added to C2-deficient serum, the reaction mixture volume increased to 0.4 ml. Control tubes lacking WBC, test serum, or complement were included in each assay. Opsonic mixtures were incubated at 37°C during end-over-end rotation in a Roto-Rack apparatus (Fisher Scientific Co., Pittsburgh, Pa.) for 40 min. When the classical pathway was inhibited by MgEGTA, the procedure was modified to include a preopsonization step to avoid toxicity to the WBC. Serum diluted 1:2 in MgEGTA or GVB++ as a control were incubated 5 min at 37°C to allow EGTA to chelate the available calcium. The procedure was then completed as described previously (18) , and the results were expressed as the bactericidal index: ) was reacted at a 1:2 dilution with opsonized and unopsonized bacteria. For these experiments, 0.1 ml of agammaglobulinemic serum or purified human Cl containing 1,000 U were reacted with strains 090 or 515 under conditions identical to those of the opsonophagocytic assays, except that WBC were replaced with 0.1 ml of MEM. The remainder of the procedure for Clq indirect immunofluorescence was identical to that described above for IgG except that a 1:3 dilution of conjugate was used.
RESULTS
Human sera that contained endogenous complement and antibody to native type Ta polysaccharide representing a range in concentration from moderate to high (7.6-32 ug/ml) to very low (<1.8-3.1 ,ug/ml) were selected for evaluation of their opsonophagocytic activity for a variety of type Ia strains. For the Lancefield prototype strain 090 only sera containing moderate to high levels of specific antibody promoted significant opsonophagocytosis (_90% reduction of CFU at 40 min) (Table I ). In contrast, sera from 25 normal adults with low antibody concentrations uniformly failed to cause bacteriolysis of this strain. Heat-inactivated sera did not promote opsonophagocytosis, des- (Table II) . When these two sera that contained moderate (9.0 ,ug/ml) or high (27.5 Mg/ml) levels of specific antibody were absorbed with whole type Ia organisms or purified native type Ia antigen, the concentration of antibody was markedly reduced, resulting in ablation of their bactericidal activity. Opsonization was unaffected when these same sera were absorbed with purified type 3 pneumococcal polysaccharide or with whole type III, group B streptococcal cells. These experiments indicate a critical role for type Ia-specific antibody in the opsonophagocytosis of the prototype Ia strain 090 by human sera in the presence of complement.
To assess possible strain differences in opsonic requirements, we compared Lancefield strain 090 with 18 fresh clinical isolates of type Ia, group B streptococci. The opsonophagocytosis of these strains by serum that contained moderate (9.0 ,ug/ml) or low (2.0 Ag/ml) levels of antibody to native type Ia polysaccharide and by agammaglobulinemic serum is summarized in Fig. 1 . Whereas opsonophagocytosis of strain 090 required specific antibody in a sufficient concentration, both serum deficient in type-specific antibody and agammaglobulinemic serum promoted opsonophagocytosis of all 18 fresh clinical isolates, as evidenced by mean bactericidal indices of 94 (range, 83-98%) and 95% (range, 77-99%), respectively. When the bactericidal activity of these three representative sera for the clinical type Ia strains were compared, no differences in opsonization were noted between iso- lates from infants with bacteremia or meningitis and those from asymptomatic adults (mean bactericidal indices, 92 and 96%, respectively). As noted for prototype strain 090, bacterial growth of the 18 clinical type la isolates always occurred in the absence of complement or WBC.
To determine whether these observed differences in opsonic requirements of adult sera for Lancefield prototype strain 090 (mouse passed 14 times) and representative fresh clinical isolates might be related to relative degree of encapsulation, we performed electron microscopy ( Fig. 2) Type Ta capsular polysaccharide from strains 090, 501, and 515 was isolated by methods described elsewhere (6) . The capsules from all three strains were identical by chemical and immunologic analyses. Each contained galactose, glucose, glucosamine, and sialic acid in molar ratios of 2:1:1:1. All gave lines of identity by double diffusion in agar gel against type Ta rabbit antisera. Extractions of these three strains with HCI yielded immunochemically identical type Ia core polysaccharides.
Employing defined sera and experimental conditions that allowed activation of both complement pathways or inhibition of the classical pathway (chelation with MgEGTA), we compared prototype strain 090 with a representative fresh type Ta isolate, 515. Although sufficient concentrations of specific antibody were required for opsonophagocytosis of 090 when both complement pathways were intact, only five of eight sera with moderate to high levels of antibody were able to recruit the alternative pathway to mediate bacterial killing when the classical pathway was blocked. (Table IV) . The inability of some chelated sera to promote opsonophagocytosis of strain 090 even in the presence of moderate levels of specific antibody is illustrated by the wide range shown in Fig. 3 . Serum deficient in antibody, agammaglobulinemic serum, and C2-deficient serum (also deficient in specific antibody) all failed to promote opsonophagocytosis of strain 090. In contrast, opsonophagocytic killing of strain 515 was mediated by the classical pathway in an antibody-independent fashion (Table V) guinea pig C2 restored the bactericidal activity of this but not low, levels of specific antibody were able to serum to 91 and 93%, respectively. Unlike what was facilitate opsonophagocytosis of strain 515 via the alobserved for strain 090, all sera containing moderate, ternative complement pathway. To further evaluate the classical pathway-mediated killing of strain 515 by serum containing low concentrations (2.0 ,ug/ml) of specific antibody, we performed a kinetic experiment (Fig. 4) . Bacterial growth was observed in tubes containing MgEGTA buffer alone, heated and MgEGTA-treated antibody-deficient serum, and no WBC, whereas a >1 logto reduction in inoculum was observed within 10 min of incubation of bacteria with antibody-deficient serum with endogenous complement. The rapidity with which opsonophagocytosis was observed was consistent with other experiments implicating classical pathway mediation.
To investigate a possible mechanism for antibodyindependent classical pathway activation by type Ia, group B streptococci, we performed the following experiments. Strain 515 was opsonized for 40 Because it is conceivable, although unlikely, that the small amount of IgG present in agammaglobulinemic serum was mediating activation of classical pathway components, and since it is possible that antibodies to a surface antigen other than the type Ia capsular polysaccharide were mediating activation of Cl and the subsequent deposition of Clq at the bacterial surface, an additional experiment was designed. Strains 090 and 515 were opsonized in the presence of purified human Cl. After washing and resuspending opsonized and unopsonized bacteria in fluorescein-labeled antihuman Clq, we noted strong (4+) fluorescence for strain 515, whereas we found no fluorescence for strain 090 or for either strain unexposed to Cl. These results confirm other evidence indicating that the classical pathway is activated by clinical isolates of type Ia, group B streptococci in the absence of type-specific antibody and that immunoglobulin is not required for fixation of Clq at the bacterial surface.
DISCUSSION
The extensive work of Lancefield and co-workers (10, (20) (21) (22) has supported the concept that protective im- munity to group B Streptococcus is mediated by antibody with specificity for the homologous capsular polysaccharide antigen (type-specific immunity). Employing prototype strains, passed in mice to enhance virulence, and type-specific rabbit antisera prepared to these strains, they were able to show passive protection after lethal challenge with homologous, but not heterologous, strains representing group B streptococcal serotypes Ia, Ib, Ic, and'II. Although type III strains were not lethal in this standard animal model, type III-specific protective immunity has now been established in models for lethal infection in mice (23) (24) (25) , chick embryos (9, 26) , and suckling rats (27 (1, 3, 8, 9, 16) . This presumably "protective" antibody has specificity for the native III polysaccharide (2, 5) , is an IgG immunoglobulin (1, 8, 9) , and is placentally transferred in concentrations that, beyond 35-36 wk of gestation, approach that in maternal serum (1, 9) . In addition, it promotes opsonophagocytosis and killing of type III strains by polymorphonuclear leukocytes in the presence of complement (4, 18) , is protective in animal models when sufficient concentrations are administered before or concomitant with challenge (9, 25, 26) , and can modify the terminal sialic acid moieties of the type III capsule in a manner that permits activation of the alternative pathway (4). Previous reports have suggested that human immunity to type Ia, group B Streptococcus is analogous to that of serotype III (7) (8) (9) 30) . In three of these studies, however, the presence of type Ia antibody in a serum was measured exclusively by functional'assays (opsonophagocytosis [7, 30] or opsonization related to chemiluminescence [8] ) that employed the mousepassed strain 090 as the only test organism. Our finding that phagocytosis and killing of this strain is dependent upon a critical amount of specific antibody (quantitated in a radioimmunoassay) is consistent with these observations (7) (8) (9) 30) . However, the notable disparity between the opsonophagocytic requirements of human sera for this laboratory-adapted, highly encapsulated strain and those for type Ia strains freshly isolated from patients described in the present study suggest that the precise role of type-specific antibody and complement in human infection due to type Ia, group B Streptococcus should be reexamined.
Opsonophagocytosis of Type Ia, Group B Streptococcus

401
The potential importance of the experiments indicating in vitro killing of type Ta patient isolates by complement-mediated phagocytosis in human serum devoid of immunoglobulin prompted attempts to define the nature of the difference between these type Ta strains and the laboratory-adapted, prototype strain. Purified polysaccharides extracted from three representative clinical isolates and from strain 090 were chemically and immunologically identical (6) . Therefore, the immunospecificity of the capsule did not vary and could not account for differences in the ability of these strains to activate the classical pathway. When the degree of encapsulation was assessed by electron microscopy, however, the prototype strain had an abundance of capsular material when compared with a representative clinical isolate (Fig. 2) . Similarly, significantly greater quantities of type Ia polysaccharide were elaborated into the growth medium by strain 090 than by three patient isolates (Table III) . That the difference in opsonophagocytic requirements by human sera for these different strains was directly related to amount of capsular polysaccharide material was shown by manipulation of the prototype strain (serial plate passage) to induce a smaller capsule. This maneuver resulted in a loss of capsule to a degree comparable to that of clinical isolates as assessed by electron microscopy, a decreased virulence for mice, and a loss of dependence on specific antibody for opsonophagocytosis by human serum. Reversion to a highly encapsulated variant was induced in this plate-passed 090 strain by serial passage in mice or in 10% human serum. Similar laboratory maneuvers for two fresh clinical isolates failed to influence opsonic requirements by human sera or mouse virulence. Selection of strain 090 as the prototype for serotype Ta by Lancefield (personal communication) was based upon its unusual degree of encapsulation compared with other strains and its ready adaptation to mouse virulence. Although selection for these characteristics enhances investigations requiring extraction of capsular material in large quantities or those defining protective antibodies in the mouse model, our inability to increase the capsular size of type Ia, group B streptococcal isolates suggests that 090 may be somewhat unique among these organisms. However, additional study of a large number of fresh clinical isolates would be required to substantiate this hypothesis.
These experiments suggest that the degree of encapsulation of type Ia, group B Streptococcus dictates the opsonophagocytic requirements by human serum. Perhaps, the abundance of capsular material on strain 090 masks surface sites that are available for direct complement activation by the fresh clinical isolates. However, the activating site is not known and other explanations for these observations are indeed possible.
Although it is not surprising that laboratory adaptation of microorganisms can influence degree of encapsulation, which, in turn, directly influences virulence in mice and opsonic requirements of adapted strains (pneumococci [31, 32] , H. influenzae type b [33] , and S. aureus [34] ), it is important to emphasize that type la isolates associated with human infection resisted procedures known to enhance encapsulation and virulence for mice. Similar to what has been reported for type III, group B Streptococcus (4, 18) in the presence of considerable amounts of type Ta-specific antibody (26 sg/ml), both the prototype strain 090 and representative clinical isolate 515 could be opsonized and killed in sera chelated with MgEGTA. Therefore, clinical isolates of both of these serotypes of group B streptococci can activate the alternative complement pathway when sera contain a sufficient amount of type-specific antibody.
The most surprising observation in this study was that clinically relevant strains of type Ia, group B Streptococcus could be opsonized and killed in low specific antibody-containing or agammaglobulinemic sera. This finding indicates that opsonophagocytosis is independent both of type-specific antibody and of antibody directed against other antigenic determinants. This antibody-independent bactericidal activity of sera was ablated by MgEGTA treatment, indicating that it requires calcium and does not involve alternative complement pathway activation. That this antibody-independent opsonophagocytosis was mediated by activation of the classical pathway was also demonstrated when serum genetically deficient in C2 could not promote bacteriolysis of strain 515 until it was reconstituted with C2.
The mechanism by which type Ta, group B streptococci initiate classical pathway activation in the absence of antibody is incompletely elucidated. In other systems, activation mediated by binding of Cl to a surface has been described. The experiments performed here indicate that immunoglobulin is not required for Clq fixation at the bacterial surface. If this Cl binding to the surface of type Ia strains can be shown to mediate activation of the classical pathway, as has been described for retroviruses (35) , C-reactive protein (36) , complexes of polyanions and polycations (37) , certain gram-negative enteric bacilli (38, 39) , and some strains of gram-positive bacteria (40) (41) (42) , the definition of the surface component of the bacterium responsible for this binding will be important.
This study demonstrates that opsonophagocytosis of clinical type Ta, group B streptococci by human sera is mediated by the classical pathway in an immunoglobulin-independent manner. Whether Cl mediates this classical pathway activation by the binding of Cl 402 to sites on the bacterial surface needs to be defined in future studies. In a preliminary study, sera from three healthy term neonates <24 h of age promoted significant opsonophagocytosis of clinical isolate 515, whereas strain 090 grew in each of these sera. It is possible, however, that the range in physiological deficiency of classical pathway components described for neonatal sera (43, 44) has critical functional significance that relates to the pathogenesis of type Ia, group B streptococcal disease in select hosts.
